Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform

Contributed by: Business Wire

Logo

Tags

Oncology

Nursing

Health

Infectious Diseases

Clinical Trials

Pharmaceutical

Biotechnology

Centivax

More Like This

Meiji Seika Pharma Opens New Office in Boston Area to Pursue Investment Opportunities in Innovative Drugs and Technologies

Meiji Seika Pharma Invests in Lyric Bio for Next-Generation Human Immunoglobulin Manufacturing

PR Newswire associated0

Centivax Selects Global CDMO BioCina to Initiate cGMP Manufacturing of Revolutionary Universal Influenza Vaccine

Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery

Meiji Seika Pharma Invests in MPM BioImpact’s New Technologies and Virology Strategy

Virometix AG Announces Completion of $15 Million Financing Round to Advance Development of V-212 and Next-Generation Synthetic Vaccines

PR Newswire associated0

BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.

Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas